Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 32448366)

  • 1. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutic agents for lung cancer.
    Dholaria B; Hammond W; Shreders A; Lou Y
    J Hematol Oncol; 2016 Dec; 9(1):138. PubMed ID: 27938382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
    Ren S; Xiong X; You H; Shen J; Zhou P
    Front Immunol; 2021; 12():689132. PubMed ID: 34149730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
    De Giglio A; Di Federico A; Nuvola G; Deiana C; Gelsomino F
    Curr Oncol Rep; 2021 Aug; 23(11):126. PubMed ID: 34453261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
    Losanno T; Gridelli C
    Curr Oncol Rep; 2021 Aug; 23(10):119. PubMed ID: 34342732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
    Su S; Chen F; Xu M; Liu B; Wang L
    Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
    Zhang S; Bai X; Shan F
    Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
    Majeed U; Manochakian R; Zhao Y; Lou Y
    J Hematol Oncol; 2021 Jul; 14(1):108. PubMed ID: 34238332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.